clinical trial · NCT06650852
A Study to Evaluate the Efficacy and Safety of Combination Therapy of BRII-179, BRII-835 and PEG-IFNα in Participants With Chronic Hepatitis B Virus (HBV) Infection (ENHANCE)
Chronic Hepatitis B Virus (HBV) InfectionBRII-179BRII-835 (VIR-2218)PEG-IFNαPlacebo of BRII-179Placebo of BRII-835
brief summary
This Phase 2, randomized, double-blind study will evaluate the clinical efficacy and safety of the combination therapy of BRII-179, BRII-835, plus PEG-IFNα compared to PEG-IFNα in adult participants with chronic HBV infection without cirrhosis receiving neucloes(t)ide reverse transcriptase inhibitors (NRTIs) as background therapy.
started
Oct 31, 2024
primary completion
Jul 1, 2026
completion
Jul 1, 2027
last updated
May 23, 2025
official title
A Phase 2 Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Combination Therapy of BRII-179, BRII-835 and Pegylated Interferon Alpha (PEG-IFNα) in Participants With Chronic Hepatitis B Virus (HBV) Infection (ENHANCE)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol